{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T21:21:52Z","timestamp":1758057712927,"version":"3.44.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1016\/j.ejphar.2005.11.004","type":"journal-article","created":{"date-parts":[[2005,11,29]],"date-time":"2005-11-29T07:41:32Z","timestamp":1133250092000},"page":"157-163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice"],"prefix":"10.1016","volume":"529","author":[{"given":"Tomomi","family":"Oki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuji","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukiko","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry I.","family":"Yamamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shizuo","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2005.11.004_bib1","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2165\/00003495-198835040-00006","article-title":"Current concepts in the treatment of disorders of micturition","volume":"35","author":"Andersson","year":"1988","journal-title":"Drugs"},{"issue":"6A Suppl","key":"10.1016\/j.ejphar.2005.11.004_bib2","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0090-4295(97)00599-2","article-title":"Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis","volume":"50","author":"Appell","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.ejphar.2005.11.004_bib3","first-page":"287","article-title":"Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity","volume":"35","author":"Brynne","year":"1997","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2005.11.004_bib4","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0163-7258(93)90027-B","article-title":"Muscarinic receptors: characterization, coupling and function","volume":"58","author":"Caulfield","year":"1993","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2005.11.004_bib5","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/0024-3205(88)90398-0","article-title":"Characterization of muscarinic receptor subtypes in human tissues","volume":"43","author":"Giraldo","year":"1988","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2005.11.004_bib6","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1592\/phco.19.4.267.30943","article-title":"Tolterodine, a new antimuscarinic drug for treatment of bladder overactivity","volume":"19","author":"Guay","year":"1999","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ejphar.2005.11.004_bib7","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1146\/annurev.pa.30.040190.003221","article-title":"Muscarinic receptor subtypes","volume":"30","author":"Hulme","year":"1990","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejphar.2005.11.004_bib8","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with the Folin phenol reagent","volume":"193","author":"Lowry","year":"1951","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2005.11.004_bib9","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0014-2999(97)89661-6","article-title":"Tolterodine\u2014a new bladder-selective antimuscarinic agent","volume":"327","author":"Nilvebrant","year":"1997","journal-title":"Eur. J. Pharmacol"},{"key":"10.1016\/j.ejphar.2005.11.004_bib10","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1600-0773.1997.tb02064.x","article-title":"Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine","volume":"81","author":"Nilvebrant","year":"1997","journal-title":"Pharmacol. Toxicol."},{"key":"10.1016\/j.ejphar.2005.11.004_bib11","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1097\/01.ju.0000138472.16876.8d","article-title":"Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder","volume":"172","author":"Oki","year":"2004","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2005.11.004_bib12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/(SICI)1099-081X(199903)20:2<91::AID-BDD162>3.0.CO;2-Y","article-title":"Serum protein binding of tolterodine and its major metabolites in humans and several animal species","volume":"20","author":"P\u00e5hlman","year":"1999","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejphar.2005.11.004_bib13","first-page":"125","article-title":"Tissue distribution of tolterodine, a muscarinic receptor antagonist, and transfer into fetus and milk in mice","volume":"51","author":"P\u00e5hlman","year":"2001","journal-title":"Arzneim-Forsch\/Drug Res."},{"key":"10.1016\/j.ejphar.2005.11.004_bib14","first-page":"134","article-title":"Pharmacokinetics of tolterodine, a muscarinic receptor antagonist, in mouse, rat and dog","volume":"51","author":"P\u00e5hlman","year":"2001","journal-title":"Arzneim.-Forsch.\/Drug Res."},{"key":"10.1016\/j.ejphar.2005.11.004_bib15","first-page":"289","article-title":"Tolterodine: a new muscarinic receptor antagonist, is metabolized by cytochrome P450 2D6 and 3A4 in human liver microsomes","volume":"26","author":"Postlind","year":"1998","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejphar.2005.11.004_bib16","first-page":"299","article-title":"Cumulative dose\u2013response curves II. Techniques for the making of dose\u2013response curves in isolated organs and the evaluation of drug parameters","volume":"143","author":"Van Rossum","year":"1963","journal-title":"Arch. Int. Pharmacodyn."},{"key":"10.1016\/j.ejphar.2005.11.004_bib17","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0022-3565(25)09628-4","article-title":"Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins","volume":"273","author":"Wang","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2005.11.004_bib18","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1532-5415.1990.tb03512.x","article-title":"Pharmacologic treatment of incontinence","volume":"38","author":"Wein","year":"1990","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.ejphar.2005.11.004_bib19","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.1464-410x.2001.02296.x","article-title":"The overactive bladder","volume":"88","author":"Wyndaele","year":"2001","journal-title":"Br. J. Urol. Int."},{"key":"10.1016\/j.ejphar.2005.11.004_bib20","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0022-3565(25)32274-3","article-title":"Characterization of alpha-1 adrenergic receptors in the heart using [3H]WB4101: effect of 6-hydroxydopamine treatment","volume":"215","author":"Yamada","year":"1980","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2005.11.004_bib21","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1038\/sj.bjp.0705371","article-title":"In vitro and ex vivo effects of a selective nociceptin\/orphanin FQ (N\/OFQ) peptide receptor antagonist, CompB, on specific binding of [3H]N\/OFQ and [35S]-GTP\u03b3S in rat brain and spinal cord","volume":"139","author":"Yamada","year":"2003","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2005.11.004_bib22","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2165\/00002512-199506030-00007","article-title":"Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability","volume":"6","author":"Yarker","year":"1995","journal-title":"Drugs Aging"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299905011337?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299905011337?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:07:11Z","timestamp":1757974031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299905011337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":22,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["S0014299905011337"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2005.11.004","relation":{},"ISSN":["0014-2999"],"issn-type":[{"type":"print","value":"0014-2999"}],"subject":[],"published":{"date-parts":[[2006,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2005.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}